AKT1 and diffuse large B-cell lymphoma: To test whether the high expression of BCL2 is correlated to the activation of PI3K-AKT pathway in DLBCL, we used the pan-PI3K inhibitor GDC-0941 and PI3Kα/δ inhibitor Copanlisib42 in treating WT SU-DHL4 cells.